<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3ADiabetes_medication%2F39%2Fen</id>
	<title>Translations:Diabetes medication/39/en - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3ADiabetes_medication%2F39%2Fen"/>
	<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Diabetes_medication/39/en&amp;action=history"/>
	<updated>2026-11-19T18:48:04Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.0</generator>
	<entry>
		<id>https://wiki.tiffa.net/w/index.php?title=Translations:Diabetes_medication/39/en&amp;diff=110583&amp;oldid=prev</id>
		<title>FuzzyBot: Importing a new version from external source</title>
		<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Diabetes_medication/39/en&amp;diff=110583&amp;oldid=prev"/>
		<updated>2024-02-04T03:09:12Z</updated>

		<summary type="html">&lt;p&gt;Importing a new version from external source&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;====Injectable glucagon-like peptide analogs and agonists====&lt;br /&gt;
Glucagon-like peptide (GLP) agonists bind to a membrane GLP receptor. As a consequence, insulin release from the pancreatic beta cells is increased. Endogenous GLP has a half-life of only a few minutes, thus an analogue of GLP would not be practical. As of 2019, the [[American Association of Clinical Endocrinologists|AACE]] lists GLP-1 agonists, along with SGLT2 inhibitors, as the most preferred anti-diabetic agents after metformin. [[Liraglutide]] in particular may be considered first-line in diabetic patients with cardiovascular disease, as it has received FDA approval for reduction of risk of major adverse cardiovascular events in patients with type 2 diabetes. In a 2011 [[Cochrane (organisation)|Cochrane]] [[Systematic review|review]], GLP-1 agonists showed approximately a 1% reduction in HbA1c when compared to placebo. GLP-1 agonists also show improvement of [[Beta cell|beta-cell]] function, but this effect does not last after treatment is stopped. Due to shorter duration of studies, this review did not allow for long-term positiver or negative effects to be assessed.&lt;br /&gt;
* [[Exenatide]] (also Exendin-4, marketed as Byetta) is the first [[glucagon-like peptide-1|GLP-1]] agonist approved for the treatment of [[type 2 diabetes]]. Exenatide is not an analogue of GLP but rather a GLP agonist. Exenatide has only 53% homology with GLP, which increases its resistance to degradation by DPP-4 and extends its half-life. A 2011 Cochrane review showed a HbA1c reduction of 0.20% more with Exenatide 2&amp;amp;nbsp;mg compared to insulin glargine, exenatide 10&amp;amp;nbsp;µg twice daily, sitagliptin and pioglitazone. Exenatide, together with liraglutide, led to greater weight loss than glucagon-like peptide analogues.&lt;br /&gt;
* [[Liraglutide]], a once-daily human analogue (97% homology), has been developed by [[Novo Nordisk]] under the brand name [[Victoza]]. The product was approved by the [[European Medicines Agency]] (EMEA) on July 3, 2009, and by the [[U.S. Food and Drug Administration]] (FDA) on January 25, 2010. A 2011 Cochrane review showed a HbA1c reduction of 0.24% more with liraglutide 1.8&amp;amp;nbsp;mg compared to insulin glargine, 0.33% more than exenatide 10&amp;amp;nbsp;µg twice daily, sitagliptin and rosiglitazone. Liraglutide, together with exenatide, led to greater weight loss than glucagon-like peptide analogues.&lt;br /&gt;
* [[Taspoglutide]] is presently in Phase III clinical trials with [[Hoffman-La Roche]].&lt;br /&gt;
* Lixisenatide (Lyxumia) Sanofi Aventis&lt;br /&gt;
* [[Semaglutide]] (Ozempic) (oral version is Rybelsus)&lt;br /&gt;
* [[Dulaglutide]] ([[Trulicity]]) - once weekly&lt;br /&gt;
* [[Albiglutide]] (Tanzeum) - once weekly&lt;/div&gt;</summary>
		<author><name>FuzzyBot</name></author>
	</entry>
</feed>